Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · SS-31Supported
Oral Colon- and Mitochondria-Targeted Nanoparticles Alleviate Ulcerative Colitis by Reeducating Macrophage Polarization via SIRT3/FOXO3a-Mediated Mitochondrial Restoration.
SS-31 here is the targeting element in a nanoparticle rather than the agent under test, so the results speak to the delivery system as a whole and cannot be read as evidence for SS-31 on its own. The mechanistic chain is well documented — mitochondrial membrane potential, ATP, ROS, mitophagy and macrophage phenotype all measured — but the model is DSS-induced colitis in mice, a short-course chemical injury that responds to many things that fail in human inflammatory bowel disease. No human data and no oral pharmacokinetics in people. Relevant to readers tracking SS-31 and elamipretide as mitochondrial-targeting tools.
Journal of gastroenterology and hepatologyn=—AnimalAug 24, 2026 - Study · SS-31Mixed
Seawater immersion reshapes the temporal dynamics of traumatic brain injury and reveals mitochondrial oxidative stress as a modifiable therapeutic target.
The headline science here is the proteomics — seawater immersion as a temporal modifier of secondary brain injury — with SS-31 deployed as the interventional probe. The peptide's showing is genuinely mixed: it blunted several inflammatory, redox, and white-matter abnormalities, but only partially, and the authors themselves position mitochondrial oxidative stress as one modifiable node among several. This fits the existing preclinical pattern for SS-31 in neurotrauma: consistent partial signals, no human data. Worth logging as another animal-model data point, framed accordingly.
Experimental neurologyn=—AnimalAug 14, 2026 - Study · SS-31Supported
Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats.
The most useful detail for anyone tracking SS-31 is the timing: the peptide was given four weeks after surgery, well after the injury window, and memory still recovered. That argues the deficit is sustained by ongoing bioenergetic failure rather than by fixed structural damage. Worth noting that memory recovered while DNA oxidation and the axonal damage marker remained high, so the peptide appears to restore function without reversing the underlying oxidative burden. This is aged-rat work with no human data behind it.
Brain, behavior, and immunityn=—AnimalAug 3, 2026 - Study · SS-31Weak / none
Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.
This preclinical mouse study directly administered elamipretide (SS-31) and reported associations with improved oxidative-stress markers and reduced mitochondrial DNA leak in acute lung injury. SS-31 is a genuine intervention arm here, though the strongest effects came from its combination with a separate STING inhibitor, making its isolated contribution partial. As early animal work, the evidence is preliminary but the peptide is a real subject of the study.
Tissue & celln=—AnimalAug 1, 2026 - Study · SS-31Weak / none
Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.
A cell-culture study in which SS-31 was the direct intervention and showed a consistent signal against radiation-induced senescence markers. Findings are mechanistic and preclinical, not evidence of clinical benefit in people.
Journal of radiation researchn=—In vitroJul 15, 2026 - Study · SS-31Supported
Elamipretide: a mitochondria-targeting drug for Barth syndrome.
This review covers elamipretide (SS-31) for Barth syndrome, a use recently supported by regulatory approval. As a brief review it summarizes rather than generates evidence, but it centers a tracked peptide with a clear clinical narrative. Supports a measured, non-promotional writeup noting the ultra-rare indication.
Trends in pharmacological sciencesn=——Jul 14, 2026 - Study · SS-31Weak / none
Elamipretide in pediatric Barth syndrome: from heart failure to school return.
A single pediatric case report of elamipretide (SS-31) in Barth syndrome, with notable improvement alongside maximal standard therapy. As an uncontrolled n-of-1 report it cannot establish causation and one transient adverse event was noted. Carefully framed as a single-patient observation.
Orphanet journal of rare diseasesn=—HumanJul 7, 2026 - Study · SS-31Weak / none
Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.
A controlled rat study showing SS-31 improving skeletal-muscle function in a HFpEF model, with a plausible cardiolipin-stabilization mechanism. Evidence remains preclinical and animal-only.
Circulation. Heart failuren=—AnimalJun 15, 2026 - Study · SS-31Weak / none
Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.
A laboratory study using cell cultures and biochemical assays, not human data. SS-31 has been studied for its effects on mitochondrial function and protein aggregation relevant to Parkinson's-type pathology. Findings are early-stage and warrant further preclinical work.
Chemical biology & drug designn=—In vitroJun 1, 2026